Swixx Biopharma, UAB - financials and debts

Company age: 11 y. 9 mo.

Update

Swixx Biopharma - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 1,095,114 1,374,921 1,529,790 2,011,147 5,166,407 5,786,464 5,753,408 5,937,094
Profit before tax 50,449 56,864 75,657 102,953 301,363 381,645 325,690 483,273
Net profit 39,314 50,086 62,037 84,739 264,118 302,989 273,862 403,639
Equity 146,007 195,817 253,936 338,675 602,793 905,783 1,179,645 1,583,284
Liabilities 170,564 192,901 266,965 391,148 580,246 769,783 786,347 811,664
Non-current assets 21,581 21,607 44,532 101,251 96,663 109,242 82,301 57,037
Current assets 281,074 351,958 462,703 610,765 1,035,103 1,466,233 1,811,460 2,194,987
Total assets 302,655 373,565 507,235 712,016 1,131,766 1,575,475 1,893,761 2,252,024
Taxes paid
STI taxes - - - - - 582,812 603,523 636,577
Social insurance contributions - - - - - 671,106 718,669 748,233
Financial indicators
Revenue change y/y +26.5% +25.6% +11.3% +31.5% +156.9% +12.0% -0.6% +3.2%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 13.0% 13.4% 12.2% 11.9% 23.3% 19.2% 14.5% 17.9%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 26.9% 25.6% 24.4% 25.0% 43.8% 33.5% 23.2% 25.5%
Profit margin Net profit margin. Shows the overall profitability of the company. 3.6% 3.6% 4.1% 4.2% 5.1% 5.2% 4.8% 6.8%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 4.6% 4.1% 4.9% 5.1% 5.8% 6.6% 5.7% 8.1%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 1.2 1.0 1.1 1.2 1.0 0.8 0.7 0.5
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 121,679 135,238 129,278 139,501 126,783 138,875 130,759 141,359

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

Sales revenue

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Swixx Biopharma - Social security debts

From To Debt, €
2025-07-24 2025-08-05 0.17
2025-01-31 2025-02-11 0.15
2025-01-22 2025-01-29 0.15
2023-12-18 2023-12-20 0.01
2023-12-01 2023-12-13 0.01
2023-08-17 2023-08-20 0.70
2023-07-28 2023-08-13 0.70
2023-07-24 2023-07-25 0.72
2023-06-16 2023-06-20 72.37
2023-05-16 2023-06-14 72.37
2023-02-17 2023-02-20 0.03
2022-12-16 2022-12-19 75.35
2022-09-16 2022-09-19 46542.58

Swixx Biopharma - VMI tax arrears

From To Overdue, €
2025-11-12 2025-11-12 2036.75

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Swixx Biopharma, UAB (code 303481894) is a Private Limited Liability Company operating in market research and public opinion polling. In 2025, revenue reached €5.94M, increasing by 3.2% year on year and by 2.6% over two years. Net profit rose to €403.6K, compared with €273.9K in 2024 and €303.0K in 2023, while the profit margin improved to 6.8% from 4.8% and 5.2% respectively. Total assets grew to €2.25M in 2025 from €1.89M in 2024 and €1.58M in 2023. Equity strengthened to €1.58M, while liabilities increased moderately to €811.7K. The equity ratio stood at 70.3% and debt-to-equity at 0.51, indicating a sound balance sheet position. Return on equity was 25.5% and return on assets 17.9%, supported by asset turnover of 2.64x. Revenue per employee was €141.4K and profit per employee €9.6K, suggesting a productive operating profile.